Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Bertelson

Behavioral Neurology & Neuropsychiatry Austin, TX Medical Doctor

NPI 1215959697 CMS profile 146474

1600 W 38Th St, Suite 308, Austin, TX 78731

Open in the dashboard

General payments

$312,915

578 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$355,809 paid to institutions, not to them · program year 2025

Through program year 2025, John Bertelson of Austin, TX is reported in the CMS Open Payments database as having received $312,915 across 578 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $355,809 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Behavioral Neurology & Neuropsychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $111,057 167
2024 General $133,231 188
2023 General $38,579 88
2022 General $1,187 59
2021 General $22,659 52
2020 General $4,366 5
2019 General $1,836 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Bertelson
  • Behavioral Neurology & Neuropsychiatry median
  • Middle half of Behavioral Neurology & Neuropsychiatry
  • National median

In program year 2025, general payments to John Bertelson were reported at $111,057. Among 74 Behavioral Neurology & Neuropsychiatry profiles paid that year, the median was $152 and the middle half received between $53 and $1,035.

Show as a table
Year John Bertelson Behavioral Neurology & Neuropsychiatry median Middle half National median
2019 $1,836 $211 $86–$990 $163
2020 $4,366 $270 $54–$1,600 $114
2021 $22,659 $267 $60–$1,036 $132
2022 $1,187 $255 $69–$1,314 $149
2023 $38,579 $170 $50–$1,103 $160
2024 $133,231 $173 $39–$1,488 $164
2025 $111,057 $152 $53–$1,035 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eisai Inc. $246,530 291 payments
  2. Lilly USA, LLC $33,396 61 payments
  3. Biogen, Inc. $26,374 26 payments
  4. OnMark, Inc. $1,400 1 payment
  5. Corium, Inc. $1,134 10 payments
  6. Janssen Pharmaceuticals, Inc $554 28 payments
  7. Lundbeck LLC $553 24 payments
  8. ACADIA Pharmaceuticals Inc $482 23 payments
  9. Teva Pharmaceuticals USA, Inc. $447 24 payments
  10. Neurocrine Biosciences, Inc. $437 18 payments
  11. Other $1,608 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $170,570 100 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $87,386 45 payments
  3. Consulting Fee $23,394 12 payments
  4. Travel and Lodging $20,004 89 payments
  5. Food and Beverage $11,558 331 payments
  6. Education $3 1 payment
Products named General payments · program years 2019–2025
  1. Leqembi $243,964 262 payments
  2. KISUNLA $32,097 47 payments
  3. ADLARITY $1,134 10 payments
  4. SPRAVATO $554 28 payments
  5. REXULTI Psychiatry $506 22 payments
  6. NUPLAZID $417 20 payments
  7. REXULTI Psychiatry $342 15 payments
  8. Auvelity $189 8 payments
  9. AUSTEDO $185 11 payments
  10. INGREZZA $179 9 payments
  11. Other $2,296 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

740

Median for Neurology: 833

Drug cost

$58,942

Median for Neurology: $202,670

Branded share of claims

31.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Namzaric Memantine Hcl/Donepezil Hcl Brand 14 $22,683
Memantine Hcl Er Memantine Hcl Brand 194 $14,846
Rivastigmine Generic 59 $7,460
Xarelto Rivaroxaban Brand 13 $6,702
Donepezil Hcl Generic 158 $1,990
Memantine Hcl Generic 59 $1,942
Sertraline Hcl Generic 41 $631
Duloxetine Hcl Generic 31 $612
Escitalopram Oxalate Generic 74 $534
Divalproex Sodium Er Divalproex Sodium Brand 15 $494

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$41,362

Medicare's payments for the services billed

Medicare patients

183

Average age 77

Services billed

337

88 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Alzheimer's or dementia 63%
Arthritis 42%
Ischemic heart disease 33%
Depression 29%
Chronic kidney disease 22%
Atrial fibrillation 17%
Diabetes 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $118,172
$118,172 — —
KISUNLA
  • Lilly USA, LLC $11,273
$11,273 — —
REXULTI
  • Lundbeck LLC $161
  • Otsuka America Pharmaceutical, Inc. $142
$303 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $137
$137 — —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

578 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Behavioral Neurology & Neuropsychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record